was read the article
array:23 [ "pii" => "S1579212915004371" "issn" => "15792129" "doi" => "10.1016/j.arbr.2015.10.020" "estado" => "S300" "fechaPublicacion" => "2016-02-01" "aid" => "1268" "copyright" => "SEPAR" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2016;52:57-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1662 "formatos" => array:3 [ "EPUB" => 114 "HTML" => 1105 "PDF" => 443 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0300289615004445" "issn" => "03002896" "doi" => "10.1016/j.arbres.2015.10.001" "estado" => "S300" "fechaPublicacion" => "2016-02-01" "aid" => "1268" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2016;52:57-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3320 "formatos" => array:3 [ "EPUB" => 98 "HTML" => 2357 "PDF" => 865 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "GOLD: puntos a favor" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "57" "paginaFinal" => "58" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "GOLD: Its Good Points" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Patricia Sobradillo Ecenarro, David Bravo Blanco" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Patricia" "apellidos" => "Sobradillo Ecenarro" ] 1 => array:2 [ "nombre" => "David" "apellidos" => "Bravo Blanco" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212915004371" "doi" => "10.1016/j.arbr.2015.10.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212915004371?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289615004445?idApp=UINPBA00003Z" "url" => "/03002896/0000005200000002/v1_201601280037/S0300289615004445/v1_201601280037/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1579212915004395" "issn" => "15792129" "doi" => "10.1016/j.arbr.2015.10.021" "estado" => "S300" "fechaPublicacion" => "2016-02-01" "aid" => "1275" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2016;52:59-60" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2253 "formatos" => array:3 [ "EPUB" => 126 "HTML" => 1523 "PDF" => 604 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "How can Patients With Asthma-COPD Overlap Syndrome in Clinical Practice be Identified?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "59" "paginaFinal" => "60" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Cómo podemos identificar a los pacientes con fenotipo mixto asma-EPOC (ACOS) en la práctica clínica?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miriam Barrecheguren, Cristina Esquinas, Marc Miravitlles" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Miriam" "apellidos" => "Barrecheguren" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Esquinas" ] 2 => array:2 [ "nombre" => "Marc" "apellidos" => "Miravitlles" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289615004548" "doi" => "10.1016/j.arbres.2015.10.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289615004548?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212915004395?idApp=UINPBA00003Z" "url" => "/15792129/0000005200000002/v1_201601300120/S1579212915004395/v1_201601300120/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "GOLD: Its Good Points" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "57" "paginaFinal" => "58" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Patricia Sobradillo Ecenarro, David Bravo Blanco" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Patricia" "apellidos" => "Sobradillo Ecenarro" "email" => array:1 [ 0 => "psobradillo@separ.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "David" "apellidos" => "Bravo Blanco" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Neumología, Hospital Universitario Araba, Vitoria, Álava, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "GOLD: puntos a favor" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">In 1998, the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) was created as a collaborative effort between the National Heart, Lung and Blood Institute (NHLBI) and the World Health Organization (WHO). Its primary aim was to focus attention on and to improve treatment and prevention of chronic obstructive lung disease (COPD). Other objectives were to promote research and provide educational support in this area throughout the world. These objectives are being achieved with the help of patient organizations and foundations, the pharmaceutical industry, government agencies, healthcare suppliers, and stakeholders in COPD research, patient care, and health promotion and disease prevention.</p><p id="par0010" class="elsevierStylePara elsevierViewall">This year, SEPAR is celebrating its “COPD-Smoking Year”, the main aim of which is to raise public awareness of COPD and the impact of smoking. It has been 15 years since GOLD published its first strategy paper,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a> bringing together the knowledge needed to provide a route map for achieving these objectives.</p><p id="par0015" class="elsevierStylePara elsevierViewall">After a year as national delegate for GOLD in Spain, I would summarize the distinctive features and strengths of this strategy as follows:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">(1)</span><p id="par0020" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Structure.</span> GOLD is a non-profit-making, non-governmental organization, set up according to formal statutes. It consists of an Executive Committee, a Scientific Committee and 2 staff members (an Executive Director and a Scientific Director).<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a> The Executive Committee meets on a yearly basis and the Scientific Committee meets before the American Thoracic Society (ATS) and European Respiratory Society (ATS) annual meetings. GOLD consists of an expert panel of respiratory medicine specialists, epidemiologists, and health educators. To free itself from dependence on contributions from the pharmaceutical industry, since July 1, 2014, GOLD activities have been funded by revenue from the sale of their documents and resources. These materials can be downloaded from the GOLD website (<a id="intr0010" class="elsevierStyleInterRef" href="http://www.goldcopd.org/">http://www.goldcopd.org</a>).</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">(2)</span><p id="par0025" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Revisions</span>. In 2001, the GOLD program published its first consensus document, The Global Strategy for the Diagnosis, Management, and Prevention of COPD.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a> Since then, the guidelines have been updated annually, and in compliance with the original 5-yearly program, they were revised in 2006 and 2011. In the future, in view of the large amount of scientific evidence published every year, we will no longer differentiate between the yearly updates and the 5-yearly revisions. Future topics will include lung cancer screening in COPD patients, the role of statins, withdrawal of inhaled corticosteroids, and comorbidities.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">(3)</span><p id="par0030" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Evidence-based medicine</span>. Since the inception of GOLD, recommendations have been classified according to the level of evidence adjudicated by the authors [from A (randomized clinical trials) to D (expert panels)]. This grading reflects the strength of the evidence supporting each recommendation.</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">(4)</span><p id="par0035" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Clinical impact</span>. It is unclear whether pharmacological treatment of COPD has changed since the initial version of the document. The latest revision of the GOLD strategy (2011)<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">3</span></a> presented a new approach to the multidimensional evaluation of COPD patients in which not only FEV1, but also the patient's burden of symptoms and the risk of future exacerbations are taken into account. Several studies have used existing patient cohorts initially recruited for other purposes in an attempt to validate this new approach to COPD. For example, Lange et al.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">4</span></a> studied 6628 COPD patients in a 4-year follow-up, concluding that: (1) the new GOLD classification properly identified patients at risk of exacerbations (the percentage of exacerbations during the first year was 2.2%, 5.8%, 25% and 28.6% in groups A, B, C, and D, respectively), although the risk of exacerbation in C and D was limited exclusively to frequent exacerbators, but not to those with a FEVI<50%; and (2) despite being theoretically classified as low risk, patients in group B had a higher mortality than those in group C, probably due to cardiovascular or oncological comorbidities.</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">(5)</span><p id="par0040" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">GOLD around the world</span>. Firstly, the GOLD consensus has inspired and formed the basis for numerous other clinical guidelines worldwide. A COPD opinion leader network, which participates actively in GOLD, has been set up in several countries. These GOLD national delegates share their ideas and work toward implementing care programs to meet the objectives of the GOLD program.</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">(6)</span><p id="par0045" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Website.</span> To facilitate international communication, GOLD launched a website with the latest news on all GOLD activities and access to educational materials for patients and the general public, available in multiple languages.</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">(7)</span><p id="par0050" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">World COPD Day</span>. GOLD organizes the World COPD Day on the third Wednesday of November, working with healthcare professionals and COPD patient associations to hold awareness-raising events and COPD educational events all over the world. Every year, GOLD chooses a theme and coordinates the preparation and distribution of material for World COPD Day. These materials, together with a full list of the activities programmed for different countries, can be downloaded from the website (<a id="intr0015" class="elsevierStyleInterRef" href="http://www.goldcopd.org/wcd-home.html">http://www.goldcopd.org/wcd-home.html</a>).</p></li></ul></p><p id="par0055" class="elsevierStylePara elsevierViewall">In conclusion, the GOLD strategy paper is a living document with a worldwide impact, which aims to improve awareness of the disease and care of COPD patients. In the future, GOLD will expand its activities via the website. A greater number of translations will be available online, and apps will be created to facilitate access from a variety of platforms.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Sobradillo Ecenarro P, Bravo Blanco D. GOLD: puntos a favor. Arch Bronconeumol. 2016;52:57–58.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0025" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "GOLD Scientific Committee" "etal" => false "autores" => array:5 [ 0 => "R.A. Pauwels" 1 => "A.S. Buist" 2 => "P.M. Calverley" 3 => "C.R. Jenkins" 4 => "S.S. Hurd" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.163.5.2101039" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2001" "volumen" => "163" "paginaInicial" => "1256" "paginaFinal" => "1276" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11316667" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0030" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD executive summary" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Vestbo" 1 => "S. Hurd" 2 => "A. Agusti" 3 => "P. Jones" 4 => "C. Vogelmeier" 5 => "A. Anzueto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201204-0596PP" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2013" "volumen" => "187" "paginaInicial" => "347" "paginaFinal" => "365" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22878278" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0035" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "GOLD bylaws. Available from: <a id="intr0020" class="elsevierStyleInterRef" href="http://www.goldcopd.org/uploads/users/files/GOLD_Bylaws_Jan09.pdf">http://www.goldcopd.org/uploads/users/files/GOLD_Bylaws_Jan09.pdf</a> [accessed 28.09.15]." ] ] ] 3 => array:3 [ "identificador" => "bib0040" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Lange" 1 => "J. Marott" 2 => "J. Vestbo" 3 => "K. Olsen" 4 => "T. Ingebrigtsen" 5 => "M. Dahl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201207-1299OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2012" "volumen" => "186" "paginaInicial" => "975" "paginaFinal" => "981" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22997207" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15792129/0000005200000002/v1_201601300120/S1579212915004371/v1_201601300120/en/main.assets" "Apartado" => array:4 [ "identificador" => "46447" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15792129/0000005200000002/v1_201601300120/S1579212915004371/v1_201601300120/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212915004371?idApp=UINPBA00003Z" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 12 | 1 | 13 |
2024 October | 43 | 21 | 64 |
2024 September | 46 | 10 | 56 |
2024 August | 49 | 37 | 86 |
2024 July | 37 | 20 | 57 |
2024 June | 55 | 24 | 79 |
2024 May | 72 | 25 | 97 |
2024 April | 38 | 27 | 65 |
2024 March | 40 | 11 | 51 |
2024 February | 32 | 22 | 54 |
2023 March | 4 | 3 | 7 |
2023 February | 25 | 19 | 44 |
2023 January | 31 | 27 | 58 |
2022 December | 20 | 36 | 56 |
2022 November | 48 | 22 | 70 |
2022 October | 39 | 34 | 73 |
2022 September | 23 | 25 | 48 |
2022 August | 40 | 43 | 83 |
2022 July | 23 | 46 | 69 |
2022 June | 26 | 28 | 54 |
2022 May | 32 | 34 | 66 |
2022 April | 33 | 24 | 57 |
2022 March | 35 | 28 | 63 |
2022 February | 31 | 39 | 70 |
2022 January | 29 | 34 | 63 |
2021 December | 29 | 37 | 66 |
2021 November | 34 | 35 | 69 |
2021 October | 38 | 45 | 83 |
2021 September | 29 | 41 | 70 |
2021 August | 29 | 32 | 61 |
2021 July | 23 | 22 | 45 |
2021 June | 30 | 26 | 56 |
2021 May | 30 | 30 | 60 |
2021 April | 74 | 63 | 137 |
2021 March | 33 | 24 | 57 |
2021 February | 25 | 23 | 48 |
2021 January | 21 | 9 | 30 |
2020 December | 22 | 13 | 35 |
2020 November | 21 | 15 | 36 |
2020 October | 16 | 16 | 32 |
2020 September | 11 | 9 | 20 |
2020 August | 14 | 17 | 31 |
2020 July | 36 | 21 | 57 |
2020 June | 18 | 7 | 25 |
2020 May | 27 | 16 | 43 |
2020 April | 26 | 13 | 39 |
2020 March | 20 | 12 | 32 |
2020 February | 34 | 13 | 47 |
2020 January | 23 | 16 | 39 |
2019 December | 29 | 26 | 55 |
2019 November | 28 | 15 | 43 |
2019 October | 13 | 7 | 20 |
2019 September | 24 | 12 | 36 |
2019 August | 20 | 12 | 32 |
2019 July | 17 | 14 | 31 |
2019 June | 16 | 13 | 29 |
2019 May | 32 | 14 | 46 |
2019 April | 29 | 25 | 54 |
2019 March | 29 | 16 | 45 |
2019 February | 32 | 14 | 46 |
2019 January | 31 | 14 | 45 |
2018 December | 27 | 10 | 37 |
2018 November | 48 | 20 | 68 |
2018 October | 58 | 19 | 77 |
2018 September | 24 | 12 | 36 |
2018 May | 11 | 0 | 11 |
2018 April | 27 | 4 | 31 |
2018 March | 29 | 2 | 31 |
2018 February | 43 | 7 | 50 |
2018 January | 61 | 6 | 67 |
2017 December | 69 | 9 | 78 |
2017 November | 20 | 3 | 23 |
2017 October | 15 | 5 | 20 |
2017 September | 20 | 10 | 30 |
2017 August | 23 | 8 | 31 |
2017 July | 12 | 8 | 20 |
2017 June | 26 | 9 | 35 |
2017 May | 22 | 11 | 33 |
2017 April | 28 | 12 | 40 |
2017 March | 10 | 4 | 14 |
2017 February | 5 | 7 | 12 |
2017 January | 14 | 8 | 22 |
2016 December | 21 | 9 | 30 |
2016 November | 28 | 16 | 44 |
2016 October | 42 | 20 | 62 |
2016 September | 28 | 9 | 37 |
2016 August | 27 | 2 | 29 |
2016 July | 26 | 5 | 31 |